AD Therapies Approved After 2014 AAD Guidelines

1 nov 2021 · Easing the Disease Burden of Patients with Atopic Dermatitis

00:12:06

Mechanism of action, indication, efficacy, and safety Dupilumab Crisaborole

Ouvir Ouvir novamente Continuar A reproduzir…
Subscrever Cancelar subscrição
Partilhar

Episódios

Emerging Therapies: Phase 3 Efficacy & Safety Data
1 nov 2021· Easing the Disease Burden of Patients with Atopic Dermatitis
JAK-STAT inhibitors: oral and topical JAK-STAT inhibitors vs dupilumab IL-13 antagonists IL-31 antagonists
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
AD Therapies Approved After 2014 AAD Guidelines
1 nov 2021· Easing the Disease Burden of Patients with Atopic Dermatitis
Mechanism of action, indication, efficacy, and safety Dupilumab Crisaborole
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Estão a faltar episódios?

Clique aqui para atualizar o feed.
Adherence to Evidence-Based Guidelines
1 nov 2021· Easing the Disease Burden of Patients with Atopic Dermatitis
2014 AAD Guidelines Recommendations for topical therapies Recommendations for phototherapy
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Components of Basic AD Care
1 nov 2021· Easing the Disease Burden of Patients with Atopic Dermatitis
Role of bathing and moisturizers Role of topical corticosteroids
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Unmet Needs in AD Care
1 nov 2021· Easing the Disease Burden of Patients with Atopic Dermatitis
Direct and indirect effects of AD Discordance in disease burden between providers and patients Rates of inadequate disease control
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.